Vericel Corp
NASDAQ:VCEL
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
32.52
59.11
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one VCEL stock under the Base Case scenario is 29.41 USD. Compared to the current market price of 59.11 USD, Vericel Corp is Overvalued by 50%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Vericel Corp
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for VCEL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Vericel Corp
Balance Sheet Decomposition
Vericel Corp
Current Assets | 190.5m |
Cash & Short-Term Investments | 101.7m |
Receivables | 48.5m |
Other Current Assets | 40.3m |
Non-Current Assets | 199.9m |
Long-Term Investments | 32.9m |
PP&E | 160m |
Intangibles | 6.4m |
Other Non-Current Assets | 610k |
Current Liabilities | 41.3m |
Accounts Payable | 20.9m |
Accrued Liabilities | 20.5m |
Non-Current Liabilities | 91.6m |
Long-Term Debt | 243k |
Other Non-Current Liabilities | 91.3m |
Earnings Waterfall
Vericel Corp
Revenue
|
226.8m
USD
|
Cost of Revenue
|
-64.7m
USD
|
Gross Profit
|
162.1m
USD
|
Operating Expenses
|
-163.3m
USD
|
Operating Income
|
-1.2m
USD
|
Other Expenses
|
4.8m
USD
|
Net Income
|
3.5m
USD
|
Free Cash Flow Analysis
Vericel Corp
USD | |
Free Cash Flow | USD |
VCEL Profitability Score
Profitability Due Diligence
Vericel Corp's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
Vericel Corp's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
VCEL Solvency Score
Solvency Due Diligence
Vericel Corp's solvency score is 85/100. The higher the solvency score, the more solvent the company is.
Score
Vericel Corp's solvency score is 85/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VCEL Price Targets Summary
Vericel Corp
According to Wall Street analysts, the average 1-year price target for VCEL is 60.56 USD with a low forecast of 56.56 USD and a high forecast of 68.25 USD.
Dividends
Current shareholder yield for VCEL is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
VCEL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 281 full-time employees. The firm is focused on therapies for the sports medicine and severe burn care markets. The company markets two autologous cell therapy products in the United States, which include MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). MACI is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel is a permanent skin replacement humanitarian use device (HUD) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area (TBSA). Its NexoBrid, is a registration-stage, topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns.
Officers
The intrinsic value of one VCEL stock under the Base Case scenario is 29.41 USD.
Compared to the current market price of 59.11 USD, Vericel Corp is Overvalued by 50%.